Xencor Inc Stock Performance
| XNCR Stock | USD 8.97 0.10 1.10% |
The firm maintains a market beta of 2.02, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Xencor will likely underperform. At this point, Xencor Inc has a negative expected return of -0.15%. Please make sure to check out Xencor's treynor ratio, kurtosis, as well as the relationship between the Kurtosis and day typical price , to decide if Xencor Inc performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Xencor Inc has generated negative risk-adjusted returns adding no value to investors with long positions. Even with latest weak performance, the Stock's fundamental indicators remain invariable and the latest agitation on Wall Street may also be a sign of long-running gains for the enterprise retail investors. ...more
| Begin Period Cash Flow | 54.2 M | |
| Total Cashflows From Investing Activities | -7.9 M |
Xencor Relative Risk vs. Return Landscape
If you would invest 1,060 in Xencor Inc on April 21, 2025 and sell it today you would lose (163.00) from holding Xencor Inc or give up 15.38% of portfolio value over 90 days. Xencor Inc is currently does not generate positive expected returns and assumes 4.7969% risk (volatility on return distribution) over the 90 days horizon. In different words, 42% of stocks are less volatile than Xencor, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Xencor Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Xencor's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Xencor Inc, and traders can use it to determine the average amount a Xencor's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0306
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | XNCR |
Estimated Market Risk
| 4.8 actual daily | 43 57% of assets are more volatile |
Expected Return
| -0.15 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.03 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Xencor is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Xencor by adding Xencor to a well-diversified portfolio.
Xencor Fundamentals Growth
Xencor Stock prices reflect investors' perceptions of the future prospects and financial health of Xencor, and Xencor fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Xencor Stock performance.
| Return On Equity | -0.34 | ||||
| Return On Asset | -0.11 | ||||
| Profit Margin | (1.63) % | ||||
| Operating Margin | (1.32) % | ||||
| Current Valuation | 236.66 M | ||||
| Shares Outstanding | 71.17 M | ||||
| Price To Earning | 69.81 X | ||||
| Price To Book | 1.00 X | ||||
| Price To Sales | 5.02 X | ||||
| Revenue | 110.49 M | ||||
| EBITDA | (186.17 M) | ||||
| Cash And Equivalents | 511.92 M | ||||
| Cash Per Share | 8.57 X | ||||
| Total Debt | 231.95 M | ||||
| Debt To Equity | 0.06 % | ||||
| Book Value Per Share | 8.99 X | ||||
| Cash Flow From Operations | (202.19 M) | ||||
| Earnings Per Share | (3.04) X | ||||
| Total Asset | 951.95 M | ||||
| Retained Earnings | (704.04 M) | ||||
| Current Asset | 97.67 M | ||||
| Current Liabilities | 43.43 M | ||||
About Xencor Performance
Assessing Xencor's fundamental ratios provides investors with valuable insights into Xencor's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Xencor is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California. Xencor operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 254 people.Things to note about Xencor Inc performance evaluation
Checking the ongoing alerts about Xencor for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Xencor Inc help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Xencor Inc generated a negative expected return over the last 90 days | |
| Xencor Inc has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 110.49 M. Net Loss for the year was (236.54 M) with loss before overhead, payroll, taxes, and interest of (102.16 M). | |
| Xencor Inc currently holds about 511.92 M in cash with (202.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.57. | |
| Xencor Inc has a frail financial position based on the latest SEC disclosures | |
| Over 99.0% of the company outstanding shares are owned by institutional investors |
- Analyzing Xencor's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Xencor's stock is overvalued or undervalued compared to its peers.
- Examining Xencor's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Xencor's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Xencor's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Xencor's stock. These opinions can provide insight into Xencor's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Xencor Stock Analysis
When running Xencor's price analysis, check to measure Xencor's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xencor is operating at the current time. Most of Xencor's value examination focuses on studying past and present price action to predict the probability of Xencor's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xencor's price. Additionally, you may evaluate how the addition of Xencor to your portfolios can decrease your overall portfolio volatility.